Overview
Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid
Description
The Role of an EsoDuo® to Control Reflux Symptoms Related to the Acid; a Multicenter, Open-labeled, Phase 4 Study [RACER Study]
Eligibility
Inclusion Criteria:
- Male or Female aged ≥ 19 years
- Patients diagnosed with non-erosive reflux disease or mild erosive reflux disease
- Episode of heartburn the GERD symptom(either heartburn or gastric acid reflux)
Exclusion Criteria:
- Surgery history on stomach or esophagus
- Barrett's esophagus (over 3cm), esophageal varices, esophageal stricture, esophageal achalasia, eosinophilic esophagitis, and primary motility disorders
- Patients diagnosed with Grade C or Grade D according to the LA Classification system during upper gastrointestinal endoscopy
- Patients with a history of malignancy within the past 5 years prior to the screening visit (Visit 1)
- Patients who have taken prohibited concomitant medications within 14 days prior to the screening visit or require continuous administration of prohibited medications during the trial period.
- Clinically significant Abnormal Lab test
- Pregnant woman, Breastfeeding woman.